Life Science RE
What’s some nuanced analysis on the life science CRE market?
Know VC funding is down given interest rate environment and this has a direct effect on transaction volume for life science.
Overbuilt primary markets like BOS, SF, SD have led to high vacancies and assume lower underwritten rents. Tenants probably have the upper hand against owners struggling with assets with murky valuations.
Anything else I’m missing?
The life science CRE market is indeed facing some challenges, and your observations are spot on. Here's a more nuanced analysis based on the most helpful WSO content:
VC Funding and Tenant Demand: As you mentioned, the decline in VC funding due to the current interest rate environment is a significant factor. This directly impacts the ability of life science companies, especially startups, to secure space. With reduced funding, many tenants are scaling back or delaying expansion plans, which contributes to higher vacancies.
Overbuilt Markets and Tenant Leverage: Primary markets like Boston (BOS), San Francisco (SF), and San Diego (SD) are indeed overbuilt, leading to elevated vacancy rates. This oversupply gives tenants more negotiating power, allowing them to push for lower rents, better concessions, or shorter lease terms. Owners of these assets are likely grappling with valuation challenges, especially as cap rates adjust upward in response to rising interest rates.
Specialized Space Requirements: Life science properties often require highly specialized buildouts, such as wet labs, clean rooms, and advanced HVAC systems. This makes it harder for landlords to repurpose or lease these spaces to non-life science tenants, further exacerbating vacancy issues in overbuilt markets.
Geographic Shifts: Secondary and tertiary markets are becoming more attractive for life science companies due to lower costs and less competition for space. Markets like Raleigh-Durham, Denver, and Austin are seeing increased interest, which could shift some demand away from traditional hubs.
Institutionalization and Long-Term Trends: Despite current headwinds, the life science sector remains a long-term growth story. The aging population, advancements in biotech, and the ongoing need for medical innovation ensure that demand for life science space will persist. However, the current market correction may lead to a flight to quality, with top-tier assets in prime locations outperforming older or less adaptable properties.
Valuation and Exit Challenges: Owners of life science assets are facing murky valuations, as you noted. Rising interest rates and reduced tenant demand are compressing exit values, making it harder for investors to achieve their target returns. This is particularly challenging for developers and owners who financed projects with floating-rate debt.
Potential Opportunities: For opportunistic investors, the current market conditions could present buying opportunities. Distressed assets in overbuilt markets or properties with motivated sellers may offer attractive entry points for those with a long-term investment horizon.
In summary, the life science CRE market is navigating a complex environment shaped by reduced funding, overbuilt conditions in key markets, and shifting tenant dynamics. However, the sector's long-term fundamentals remain strong, and strategic investors can still find opportunities amidst the challenges.
Sources: CRE’s Brave New World, What's the catch in CRE?, Depth of market and renter pool analysis, What's the catch in CRE?, CRE’s Brave New World
Life science real estate is unique in that it’s one of the few asset classes that are building for a single industry that is primarily pre-revenue.
Hyper-cyclical niche in an already cyclical industry. Has seen a massive over supply vs demand dynamic due to spec building in 2020+.
Tenant improvements have increased ~100% over the past 5 or so years. XBI performance has been horrible and companies are focused on minimizing cash burn. Major markets (SD/BOS/SF) are vastly oversupplied looking for tech tenants to take space and bail them out.
Claim to fame is that newer space is very flexible and reusable, so second generation lease up costs are minimal - probably correct but TBD.
One thing I’ve struggled with is that I can understand the case for life science trading at a (much) tighter cap rate than class A (tech) creative office, but I am not sure that should be the case anymore…
All comments spot on. I will just add the worst of the pain hasn’t hit yet.
Groups are getting desperate to fill space and will keep dropping rents. Eventually there will be plenty of examples of $0 nnn and that will seriously spook the market. Projects going back to lender will reset basis lower.
Demand is definitely up from anemic lows. Capital generally buys the story of the industry in the long run and are still paying top dollar to be in the best submarkets.
The difference between office and life science is it’s not outrageous to posit that the amount of leased life science space will be up by 50% in 10 years. Pharma is about to experience meaningful patent cliffs so it’s a matter of when, not if, they go on acquisition binges. This could kickstart the next demand cycle.
$0 NNN as in no base rent, only reimbursements from the tenant??? If so, holy shit….
This, didn't a couple big funds just downgrade the sector and say the defaults were coming.
Good color. Does anyone have any good primers or market reports on Life Sciences nationally or NYC specifically? I have read through JLL's and CBRE's reports, but they seem to be more macro focused than getting into specifics of lease comps, sales, comps, supply pipeline, etc.
I don't think the pessimism on life sciences could possibly be overstated. Your tenants are almost entirely dependent on VC funding (ignore 2020/21, that was peak of ZIRP mania and isn't coming back.) Even when you do snag one of these tenants, there's basically two outcomes: business plan fails and they default / non-renew OR many years later they get approvals for the next viagra, and they need 5x the space, which is great, but you can't possibly plan for that since you don't know the first thing about their business or FDA approvals.
The biggest problem is your basis on development / acquisitions is so unbelievably high that it's not possible to have a plan B. It can't be adapted for anything else. Adapting a movie theater or bowling alley or 1970s office is a church picnic by comparison.
As a poster previously said, it's a hyper-cyclical industry in an already cyclical industry. I advise people to stay in niches that can / will come back if they can hold on long enough (malls, office, etc). In the case of life sciences, I don't see how you can hold on or any light at the end of the tunnel.
JEF resumed coverage of ARE recently. Worth reading that report. It's not very optimistic.
I never understood what made groups comfortable with building spec life science. Even in a low interest rate environment, the buildouts seem to vary drastically and a lot of these groups with funding simply find land and self-perform. I’m a lehman about the specifics and really the whole asset class, though.
Devil's Advocate
Supply/demand imbalance is only cyclical, not structural. Strong long-term tailwinds in place: aging population, upcoming patent cliff (fuels R&D + M&A).
Won't an upcoming patent cliff result in cost cutting measures? Pharma companies are going to have their margins squeezed, and while they might try to allocate more toward R&D, I'd expect them to probably downsize and I would think they'd also be sensitive to high rents. I also find the "structural" supply/demand argument to be weak...the growth of the life science CRE market was a bubble and almost all major life science markets are overbuilt.
Devil's Devil's Advocate: China could add Biotech to the industries they take from us https://www.bostonglobe.com/2025/04/14/business/biotech-boston-kendall-…
I don't know the first thing about Life Science but there was an article in the Boston Globe I read yesterday that was basically saying it really is armageddon, and the overbuilt supply is not the primary reason. The primary reason is that China has ramped up their own sector so much that its on par and soon to surpass the US base. Large companies like Astra Zeneca are moving research to China because they have buildings and staff basically ready to go on research whereas in the US you have to find a building, hire staff, etc. They're just more agile and educated now.
Article was titled "‘I think it is actively happening’: Is Boston’s biotech industry doomed?"
Architecto omnis dolores voluptas ex nostrum. Enim et nemo illo. Aut harum vitae ad porro.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...